Table 2.

Effect of lipid-lowering drug on the risk of AMD in Singapore Epidemiology of Eye Diseases study and in UK Biobank according to the CFH rs1061170 genetic variant

Cohort	allele	n	Method	Effect sizea	p value
SEED AMD progression				OR (95% CI)
CFH rs1061170	TT	1,281	ITPW	1.00 (0.64, 1.55)	0.983
	TT	1,281	OW	1.09 (0.72, 1.66)	0.688
	CT/CC	339	ITPW	0.41 (0.19, 0.87)	0.020
	CT/CC	339	OW	0.45 (0.22, 0.96)	0.039
UK Biobank AMD incidence				HR (95% CI)
CFH rs1061170	TT	171,893	ITPW	1.14 (0.83, 1.57)	0.416
	TT	171,893	OW	1.04 (0.79, 1.38)	0.760
	CT	209,130	ITPW	0.89 (0.67, 1.20)	0.456
	CT	209,130	OW	0.85 (0.66, 1.11)	0.230
	CC	64,704	ITPW	0.65 (0.45, 0.93)	0.019
	CC	64,704	OW	0.67 (0.47, 0.96)	0.027

SEED, Singapore Epidemiology of Eye Diseases; ITPW, inverse treatment probability weighting; OW, overlap weights.

^aThe effects are expressed as odds ratios (OR) or hazard ratios (HRs) with their 95% confidence intervals (CIs).